Mechanism of Action

Upon mixing Sealer Protein (Human) and Thrombin (Human), soluble fibrinogen is transformed into fibrin, forming a rubber-like mass that adheres to the wound surface and achieves hemostasis and sealing or gluing of tissues. TISSEEL mimics the final coagulation cascade step as it has all relevant components to form a clot. TISSEEL is effective in heparinized patients and in patients medicated with anti-platelet drugs.1

  • Do not inject directly into the circulatory system; thromboembolic events can occur.
    Do not use in individuals with a known hypersensitivity to aprotinin. Apply only as a thin layer1
  • Do not use for the treatment of severe or brisk arterial bleeding1

TISSEEL Mimics the Physiological Clot2

Normal Clot

Normal Physiological Fibrin Clot3



The building blocks of a Fibrin Sealant

  • TISSEEL is expected to be completely resorbed in 10 to 14 days1
  • Incorporation of aprotinin in the product formulation increases resistance of the fibrin sealant clot to degradation in a fibrinolytic environment11
Fibrinogen 67–106 mg/mL
Thrombin 400–625 IU/mL
Aprotinin 2250–3750 KIU/mL
TISSEEL Fibrin Sealant

The physiologic fibrin clot formed by TISSEEL
Fibrin Sealant has a high elasticity.4